Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...
The explosive rise of drugs like Ozempic and Mounjaro is shifting consumption patterns, health outcomes and pushing ...
The full size recreation of the ZX Spectrum has been so popular for Black Friday it's sold out – but not everywhere ...
Natera shows strong oncology growth, 35% revenue surge, 54% test volume rise, higher expenses and 18% overvaluation at 15x ...
Fluor Corporation owns nearly 40% of SMR nuclear company NuScale Power Corporation. From one perspective, nuclear power plant ...
While Robinhood Markets, Inc. (NASDAQ:HOOD) shareholders have had a good week with the stock up 20%, they shouldn't let their guards down. Although prices were relatively low, insiders chose to sell ...
1d
Middlemen 'cashing in on human misery' take £630m from councils desperate for housing | Money blog
Money live reporter Jess Sharp explains how the budget will impact your finances in the video below. We've also been ...
Investor's Business Daily on MSN
Stock Market Today: Dow Positive For November, But Nvidia Slides; Delayed Inflation Data Looms (Live Coverage)
Through Wednesday, the Dow Jones is up 2.6% this week, the S&P 500 index has rallied 3.2%, while the Nasdaq composite jumped ...
Video game retailer GameStop Corp. (GME) is expected to report its third-quarter 2025 results on December 2. The meme stock ...
Learn more about whether Ultragenyx Pharmaceutical Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor ...
Learn more about whether Arcus Biosciences, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback